Prodia Widyahusada Tbk PT - Asset Resilience Ratio
Prodia Widyahusada Tbk PT (PRDA) has an Asset Resilience Ratio of 7.82% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Prodia Widyahusada Tbk PT for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Prodia Widyahusada Tbk PT's Asset Resilience Ratio has changed over time. See Prodia Widyahusada Tbk PT shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Prodia Widyahusada Tbk PT's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Prodia Widyahusada Tbk PT stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp82.60 Billion | 3.21% |
| Short-term Investments | Rp118.70 Billion | 4.61% |
| Total Liquid Assets | Rp201.30 Billion | 7.82% |
Asset Resilience Insights
- Limited Liquidity: Prodia Widyahusada Tbk PT maintains only 7.82% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Prodia Widyahusada Tbk PT Industry Peers by Asset Resilience Ratio
Compare Prodia Widyahusada Tbk PT's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 57.28% |
|
Leveljump Healthcare Corp
V:JUMP |
Diagnostics & Research | 32.45% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Healius Ltd
AU:HLS |
Diagnostics & Research | 0.06% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for Prodia Widyahusada Tbk PT (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Prodia Widyahusada Tbk PT.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 17.15% | Rp487.02 Billion ≈ $28.54 Million |
Rp2.84 Trillion ≈ $166.42 Million |
-5.74pp |
| 2023-12-31 | 22.89% | Rp619.85 Billion ≈ $36.32 Million |
Rp2.71 Trillion ≈ $158.68 Million |
-3.33pp |
| 2022-12-31 | 26.22% | Rp699.95 Billion ≈ $41.01 Million |
Rp2.67 Trillion ≈ $156.43 Million |
-17.92pp |
| 2021-12-31 | 44.14% | Rp1.20 Trillion ≈ $70.31 Million |
Rp2.72 Trillion ≈ $159.30 Million |
+2.94pp |
| 2020-12-31 | 41.20% | Rp919.55 Billion ≈ $53.88 Million |
Rp2.23 Trillion ≈ $130.79 Million |
-9.12pp |
| 2019-12-31 | 50.32% | Rp1.01 Trillion ≈ $59.29 Million |
Rp2.01 Trillion ≈ $117.83 Million |
+1.75pp |
| 2018-12-31 | 48.56% | Rp937.48 Billion ≈ $54.93 Million |
Rp1.93 Trillion ≈ $113.11 Million |
-4.92pp |
| 2017-12-31 | 53.48% | Rp988.43 Billion ≈ $57.92 Million |
Rp1.85 Trillion ≈ $108.30 Million |
-11.51pp |
| 2016-12-31 | 64.99% | Rp1.19 Trillion ≈ $69.47 Million |
Rp1.82 Trillion ≈ $106.88 Million |
+64.11pp |
| 2015-12-31 | 0.88% | Rp5.10 Billion ≈ $298.72K |
Rp577.87 Billion ≈ $33.86 Million |
-0.02pp |
| 2014-12-31 | 0.90% | Rp5.70 Billion ≈ $334.14K |
Rp634.33 Billion ≈ $37.17 Million |
-0.38pp |
| 2013-12-31 | 1.28% | Rp6.56 Billion ≈ $384.22K |
Rp513.64 Billion ≈ $30.10 Million |
-- |
About Prodia Widyahusada Tbk PT
PT Prodia Widyahusada Tbk provides clinical laboratory services primarily in Indonesia. The company offers laboratory, genomic, non-laboratory, and panel test services. It also operates Prodia specialty clinics; and offers vaccination, doctor consultation, and home services. It serves to individuals, doctors, and corporate and partnerships. The company was founded in 1973 and is headquartered in … Read more